axitinib,sunitinib,pembrolizumab
merck,pfizer
['axi/', 'pembro']
rrs + pfs remain impressive for axi pembro at 5 yrs. pfs plateaus at 20%. the os hr is 0.84 in itt + 0.76 in int/poor. these data show axi/pembro is excellent at disease control. the hr is less impressive than 0.53 at the start but remains competitive in int/poor risk #asco2023 
Interested in Urology Cancers, biomarkers and drug development.